Cambrian Biopharma Inc Buys 9,202 Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Cambrian Biopharma Inc purchased 9,202 shares of Sensei Biotherapeutics stock in a transaction that occurred on Wednesday, January 12th. The stock was acquired at an average price of $5.22 per share, with a total value of $48,034.44. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Cambrian Biopharma Inc also recently made the following trade(s):

  • On Wednesday, December 29th, Cambrian Biopharma Inc purchased 69,000 shares of Sensei Biotherapeutics stock. The stock was acquired at an average price of $4.98 per share, with a total value of $343,620.00.
  • On Monday, December 27th, Cambrian Biopharma Inc purchased 3,712 shares of Sensei Biotherapeutics stock. The stock was acquired at an average price of $5.30 per share, with a total value of $19,673.60.
  • On Thursday, December 16th, Cambrian Biopharma Inc purchased 10,925 shares of Sensei Biotherapeutics stock. The stock was acquired at an average price of $5.25 per share, with a total value of $57,356.25.

SNSE stock opened at $5.24 on Friday. The company has a fifty day moving average price of $6.69 and a 200 day moving average price of $8.15. Sensei Biotherapeutics, Inc. has a 12 month low of $4.70 and a 12 month high of $26.50.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Monday, November 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.07). On average, equities research analysts forecast that Sensei Biotherapeutics, Inc. will post -1.37 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Citigroup Inc. grew its stake in Sensei Biotherapeutics by 565.5% in the 3rd quarter. Citigroup Inc. now owns 2,409 shares of the company’s stock valued at $25,000 after acquiring an additional 2,047 shares during the last quarter. Royal Bank of Canada grew its stake in Sensei Biotherapeutics by 255.1% in the 3rd quarter. Royal Bank of Canada now owns 2,411 shares of the company’s stock valued at $25,000 after acquiring an additional 1,732 shares during the last quarter. New York State Common Retirement Fund grew its stake in Sensei Biotherapeutics by 37.2% in the 2nd quarter. New York State Common Retirement Fund now owns 5,396 shares of the company’s stock valued at $53,000 after acquiring an additional 1,462 shares during the last quarter. Morgan Stanley acquired a new stake in Sensei Biotherapeutics in the 1st quarter valued at about $96,000. Finally, Wells Fargo & Company MN grew its stake in Sensei Biotherapeutics by 365.6% in the 2nd quarter. Wells Fargo & Company MN now owns 11,081 shares of the company’s stock valued at $108,000 after acquiring an additional 8,701 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response.

See Also: What is a death cross?

Insider Buying and Selling by Quarter for Sensei Biotherapeutics (NASDAQ:SNSE)

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.